BioSpace News Archive

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 13, 2020.

Angelman Syndrome is a genetic disorder that mostly affects the nervous system.

In general, studies have shown that people with Type O blood appear to be more protected than those with Type A, who are seemingly more vulnerable, according to NBC News.

Although the trial failed to meet the primary endpoint of PFS, the data for overall survival as a co-primary endpoint is not yet mature. The company plans to continue the trial until the next planned analysis.

The designation will provide for an expedited pathway for regulatory review of the preventative medication, which could come later this year.

Boston-based Dewpoint Therapeutics and Merck will collaborate to develop a novel mechanism for the treatment of HIV by harnessing Dewpoint’s proprietary platform for condensate-based drug discovery.

Itolizumab is a first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway.

The COVID-19 pandemic underscored weaknesses in critical industries in the U.S. In the pharmaceutical industry, the global nature of the business, long considered a benefit, became not just a weakness but a national security threat.

Genentech, a member of the Roche Group, announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® to Avastin®, paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival for the front-line treatment of women with newly-diagnosed advanced-stage ovarian cancer.

Increasing awareness about hygiene is the key factor resulting in popularity of the hand sanitizer.